izpis_h1_title_alt

Prevalence and treatment outcomes of childhood acute lymphoblastic leukemia in Kosovo
ID Pasha, Flaka (Author), ID Urbančič, Dunja (Author), ID Maxhuni, Rufadie (Author), ID Krasniqi, Shaip (Author), ID Grajçevci Uka, Violeta (Author), ID Mlinarič-Raščan, Irena (Author)

.pdfPDF - Presentation file, Download (777,60 KB)
MD5: 0887C0C685B4C1C0C2CCF9A198DC75E6
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/16/11/1988 This link opens in a new window

Abstract
Advances in research, including novel biomarker identification and patient stratification, have significantly improved the therapy for childhood acute lymphoblastic leukemia (ALL), though access to improved healthcare services varies across geographical regions. In an effort to evaluate the advances in therapeutic approaches, we performed a retrospective analysis of childhood ALL in Kosovo. Our retrospective analysis included 225 cases diagnosed between 2008 and 2023, representing 52% of 429 diagnosed childhood cancers. The average annual incidence was 14, with a median age diagnosis of seven years, and a male predominance (59.54%). Patients were categorized into risk groups, with the majority (43%) in the standard-risk category. We identified five different treatment protocols for this study period. Over 61% of patients achieved remission after the first chemotherapy cycle and we observed a 20% mortality rate. Survival analysis showed that 55% and 40% of patients achieved 2-year and 5-year event-free survival (EFS), respectively, with significant differences across risk groups. Treatment advancements significantly correlated with improved survival rates, achieving a 5-year overall survival (OS) of 88% in the currently used standardized AIEOP-BFM-2009 protocol. Our study emphasizes the need for continued research and customized care strategies to enhance clinical outcomes.

Language:English
Keywords:acute lymphoblastic leukemia, treatment, overall survival, event-free survival, pediatric
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:13 str.
Numbering:Vol. 16, no. 11, art. 1988
PID:20.500.12556/RUL-158178 This link opens in a new window
UDC:616.155.392+616-053.2
ISSN on article:2072-6694
DOI:10.3390/cancers16111988 This link opens in a new window
COBISS.SI-ID:196879107 This link opens in a new window
Publication date in RUL:28.05.2024
Views:91
Downloads:8
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:akutna limfoblastna levkemija, zdravljenje, pediatrija, splošno preživetje, preživetje brez dogodkov

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-0022
Name:Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-E011
Name:Sofinanciranje izvajanja mednarodnega infrastrukturnega projekta EATRIS

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back